PAUL GOULD: Open Payments
NPI 1801262316 · LAKEVILLE, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$88,210 in 126 payments from 4 companies in 2025. Trend: 2023 $88,720 · 2024 $69,587 · 2025 $88,210
Speaker / faculty: $59,150Travel & lodging: $24,024Food & beverage: $2,721Consulting: $2,315
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 107 | $81,268 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $6,745 |
| Neurocrine BioSciences, Inc. | 1 | $114 |
| E.R. Squibb & Sons, L.L.C. | 1 | $83 |
Products named: VRAYLAR, CAPLYTA, INGREZZA, COBENFY.
Industry payments across MA — which companies pay providers there.
